
Researchers, including Ania M. Jastreboff, MD, PhD, detailed the results of a phase 2 study of maridebart cafraglutide for inducing weight loss in adults living with obesity, with or without type 2 diabetes.

In her award lecture, epidemiologist Juliana C.N. Chan, MBChB, MD, FHKAM, FHKCP, FRCP, detailed her decades of data-driven research and her personal experience working with patients in a major metropolis transformed by global modernization.

While the diabetes community has yet to reach the ultimate goal of improving health outcomes for every person living with diabetes, great strides have been made. Rita Rastogi Kalyani, MD, MHS, the ADA’s President, Medicine & Science, said the path forward needs to include professional education and advocacy.

Lara Dugas, PhD, MPH, and other panelists will examine the impact of common misconceptions and summarize new insights about the dynamics of muscle mass, energy expenditure, and individual metabolism.

Alison Evert, MS, RDN, CDCES, discussed three key components of diabetes nutrition therapy in her award lecture: research, recommendations, and real-world experiences.

Artificial intelligence and machine learning are helping advance personalized medicine. Michael Snyder, PhD, will discuss how continuous glucose monitoring data is transforming diabetes subtyping and management.

A leading scholar in epidemiology and health equity, Tiffany L. Gary-Webb, PhD, MHS, will receive the inaugural Dr. Felicia Hill-Briggs Health Equity Trailblazers in Diabetes Award.

Sarah Stanley, MB, BCh, PhD, and other grant recipients shared new understanding around diabetes made possible through early-career awards from the ADA.

Dietitian Maya Feller, MS, RD, CDN, and other experts will examine people’s relationships with food, as well as how low-carb, low-fat, and plant-based diets affect disease management and overall health.

Fatima Cody Stanford, MD, MPH, MPA, MBA, MACP, and others will detail some of the considerations for the management of these chronic conditions, including weight stigma and pharmacotherapy options. The new standards of care will be published later this year.